| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Attention Deficit Disorder with Hyperactivity | 11 | 2019 | 441 | 3.66 | Why? |
| Methylphenidate | 4 | 2018 | 36 | 2.22 | Why? |
| Central Nervous System Stimulants | 5 | 2018 | 111 | 1.84 | Why? |
| Prenatal Exposure Delayed Effects | 2 | 2017 | 319 | 1.02 | Why? |
| Antidepressive Agents | 2 | 2017 | 509 | 0.93 | Why? |
| Warfarin | 4 | 2018 | 402 | 0.87 | Why? |
| Osteoporotic Fractures | 3 | 2017 | 175 | 0.73 | Why? |
| Bell Palsy | 1 | 2021 | 157 | 0.72 | Why? |
| Breakthrough Pain | 1 | 2017 | 6 | 0.72 | Why? |
| Dabigatran | 2 | 2017 | 204 | 0.72 | Why? |
| Body Height | 1 | 2018 | 100 | 0.71 | Why? |
| Research Report | 1 | 2021 | 376 | 0.66 | Why? |
| Pregnancy Complications | 2 | 2017 | 1388 | 0.61 | Why? |
| Fentanyl | 1 | 2017 | 142 | 0.60 | Why? |
| Helicobacter Infections | 4 | 2019 | 216 | 0.60 | Why? |
| Helicobacter pylori | 4 | 2019 | 262 | 0.59 | Why? |
| Hong Kong | 18 | 2021 | 3361 | 0.57 | Why? |
| Palliative Care | 2 | 2020 | 2665 | 0.53 | Why? |
| Macrolides | 1 | 2017 | 369 | 0.53 | Why? |
| Vaccines, Inactivated | 1 | 2021 | 1562 | 0.53 | Why? |
| Antipsychotic Agents | 2 | 2019 | 887 | 0.50 | Why? |
| Stomach Neoplasms | 4 | 2019 | 477 | 0.49 | Why? |
| Clarithromycin | 5 | 2019 | 112 | 0.46 | Why? |
| Atrial Fibrillation | 5 | 2018 | 2320 | 0.45 | Why? |
| Publishing | 1 | 2021 | 990 | 0.44 | Why? |
| Autism Spectrum Disorder | 1 | 2019 | 587 | 0.43 | Why? |
| Drug Delivery Systems | 1 | 2020 | 1365 | 0.42 | Why? |
| Terminal Care | 1 | 2020 | 928 | 0.41 | Why? |
| Practice Patterns, Physicians' | 4 | 2018 | 4927 | 0.40 | Why? |
| Blood Pressure | 2 | 2018 | 2198 | 0.40 | Why? |
| Research Design | 2 | 2021 | 5830 | 0.34 | Why? |
| Analgesics, Opioid | 1 | 2017 | 1070 | 0.34 | Why? |
| Health Surveys | 1 | 2018 | 2841 | 0.33 | Why? |
| Randomized Controlled Trials as Topic | 3 | 2021 | 10649 | 0.32 | Why? |
| Child | 27 | 2021 | 70012 | 0.31 | Why? |
| Hip Fractures | 3 | 2018 | 667 | 0.30 | Why? |
| Medication Errors | 2 | 2017 | 107 | 0.29 | Why? |
| Sleep Initiation and Maintenance Disorders | 1 | 2017 | 1692 | 0.28 | Why? |
| Anti-Bacterial Agents | 6 | 2019 | 10083 | 0.28 | Why? |
| Wounds and Injuries | 1 | 2017 | 1708 | 0.28 | Why? |
| Statistics as Topic | 2 | 2017 | 370 | 0.28 | Why? |
| Databases, Factual | 8 | 2019 | 6248 | 0.27 | Why? |
| Suicide | 1 | 2017 | 1500 | 0.27 | Why? |
| Antithrombins | 2 | 2018 | 353 | 0.27 | Why? |
| Pregnant Women | 1 | 2017 | 2535 | 0.26 | Why? |
| Anticoagulants | 6 | 2018 | 9563 | 0.26 | Why? |
| Alendronate | 2 | 2018 | 12 | 0.24 | Why? |
| Atomoxetine Hydrochloride | 2 | 2018 | 10 | 0.24 | Why? |
| Pediatric Obesity | 2 | 2017 | 492 | 0.23 | Why? |
| Administration, Mucosal | 1 | 2020 | 15 | 0.23 | Why? |
| Child, Preschool | 18 | 2021 | 36283 | 0.23 | Why? |
| Population | 1 | 2021 | 114 | 0.22 | Why? |
| Observational Studies as Topic | 3 | 2018 | 1887 | 0.22 | Why? |
| Amoxicillin | 2 | 2018 | 98 | 0.21 | Why? |
| Cardiovascular Diseases | 4 | 2018 | 11497 | 0.21 | Why? |
| Mefenamic Acid | 1 | 2018 | 1 | 0.20 | Why? |
| Adrenergic Uptake Inhibitors | 1 | 2018 | 11 | 0.19 | Why? |
| Propensity Score | 5 | 2019 | 2690 | 0.19 | Why? |
| Diclofenac | 1 | 2018 | 27 | 0.19 | Why? |
| Adolescent | 17 | 2021 | 86841 | 0.19 | Why? |
| Pharmacopoeias as Topic | 1 | 2017 | 8 | 0.18 | Why? |
| Celecoxib | 1 | 2018 | 49 | 0.18 | Why? |
| Phenylpropionates | 1 | 2018 | 68 | 0.18 | Why? |
| Administration, Buccal | 1 | 2017 | 17 | 0.18 | Why? |
| Leukotrienes | 1 | 2018 | 37 | 0.18 | Why? |
| Guanfacine | 1 | 2017 | 5 | 0.18 | Why? |
| Eszopiclone | 1 | 2017 | 4 | 0.18 | Why? |
| Glutamates | 1 | 2017 | 12 | 0.18 | Why? |
| Leukotriene Antagonists | 1 | 2018 | 37 | 0.17 | Why? |
| Stroke | 6 | 2018 | 8839 | 0.17 | Why? |
| Education, Nonprofessional | 1 | 2017 | 31 | 0.17 | Why? |
| Penicillins | 1 | 2019 | 132 | 0.17 | Why? |
| International Classification of Diseases | 2 | 2017 | 265 | 0.17 | Why? |
| Humans | 62 | 2021 | 930598 | 0.17 | Why? |
| Clonidine | 1 | 2017 | 31 | 0.17 | Why? |
| Health Care Surveys | 2 | 2017 | 2942 | 0.17 | Why? |
| Sleep Deprivation | 1 | 2019 | 175 | 0.17 | Why? |
| Motivational Interviewing | 1 | 2017 | 55 | 0.16 | Why? |
| Drug Administration Schedule | 3 | 2018 | 2324 | 0.16 | Why? |
| Embolism | 1 | 2018 | 136 | 0.16 | Why? |
| Iron Chelating Agents | 1 | 2017 | 79 | 0.16 | Why? |
| Male | 37 | 2021 | 367725 | 0.16 | Why? |
| Weight Reduction Programs | 1 | 2017 | 87 | 0.16 | Why? |
| Agranulocytosis | 1 | 2017 | 65 | 0.16 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2019 | 1510 | 0.16 | Why? |
| Bone Density Conservation Agents | 1 | 2018 | 209 | 0.16 | Why? |
| Adenoma | 1 | 2019 | 215 | 0.15 | Why? |
| Female | 35 | 2021 | 380317 | 0.15 | Why? |
| Siblings | 1 | 2017 | 226 | 0.15 | Why? |
| Iron Overload | 1 | 2017 | 113 | 0.15 | Why? |
| Hypoglycemic Agents | 2 | 2019 | 2165 | 0.15 | Why? |
| Poisson Distribution | 1 | 2017 | 348 | 0.15 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.15 | Why? |
| Case-Control Studies | 5 | 2021 | 17671 | 0.15 | Why? |
| Spinal Fractures | 1 | 2017 | 124 | 0.15 | Why? |
| Abbreviations as Topic | 1 | 2014 | 3 | 0.15 | Why? |
| Vitamin D Deficiency | 2 | 2021 | 1782 | 0.15 | Why? |
| Incidence | 8 | 2021 | 25622 | 0.14 | Why? |
| Developed Countries | 1 | 2018 | 500 | 0.14 | Why? |
| Behavior Therapy | 1 | 2017 | 235 | 0.14 | Why? |
| Drug Hypersensitivity | 1 | 2020 | 401 | 0.14 | Why? |
| beta-Thalassemia | 1 | 2017 | 200 | 0.14 | Why? |
| Inappropriate Prescribing | 1 | 2017 | 284 | 0.13 | Why? |
| Administration, Oral | 5 | 2019 | 2340 | 0.13 | Why? |
| Hypoglycemia | 1 | 2018 | 406 | 0.13 | Why? |
| Vitamin D | 2 | 2021 | 2904 | 0.13 | Why? |
| Pneumococcal Vaccines | 1 | 2019 | 571 | 0.13 | Why? |
| Aspirin | 2 | 2018 | 1043 | 0.13 | Why? |
| Patient Outcome Assessment | 1 | 2017 | 707 | 0.13 | Why? |
| Proportional Hazards Models | 4 | 2019 | 6543 | 0.12 | Why? |
| Administration, Intranasal | 1 | 2017 | 1132 | 0.12 | Why? |
| Office Visits | 1 | 2017 | 489 | 0.12 | Why? |
| Developing Countries | 2 | 2018 | 4283 | 0.12 | Why? |
| Depression | 1 | 2017 | 14116 | 0.12 | Why? |
| Weight Loss | 1 | 2018 | 826 | 0.12 | Why? |
| Proton Pump Inhibitors | 1 | 2017 | 377 | 0.12 | Why? |
| Healthy Lifestyle | 1 | 2017 | 447 | 0.12 | Why? |
| Accidental Falls | 1 | 2017 | 448 | 0.12 | Why? |
| Colonoscopy | 1 | 2019 | 738 | 0.12 | Why? |
| Risk Factors | 12 | 2020 | 71621 | 0.12 | Why? |
| Metformin | 1 | 2019 | 640 | 0.12 | Why? |
| Psychotropic Drugs | 1 | 2017 | 396 | 0.11 | Why? |
| Adverse Drug Reaction Reporting Systems | 1 | 2017 | 694 | 0.11 | Why? |
| Asia | 1 | 2018 | 2399 | 0.11 | Why? |
| Pyridines | 1 | 2017 | 680 | 0.11 | Why? |
| Suicide, Attempted | 1 | 2017 | 599 | 0.11 | Why? |
| Drug Monitoring | 1 | 2018 | 1408 | 0.10 | Why? |
| Health Care Costs | 1 | 2019 | 1007 | 0.10 | Why? |
| Program Evaluation | 2 | 2019 | 1929 | 0.10 | Why? |
| Melatonin | 1 | 2017 | 578 | 0.10 | Why? |
| Drug Prescriptions | 2 | 2017 | 1062 | 0.10 | Why? |
| Infant | 8 | 2021 | 30274 | 0.10 | Why? |
| Commerce | 1 | 2018 | 1109 | 0.09 | Why? |
| Precision Medicine | 1 | 2019 | 1477 | 0.09 | Why? |
| Pneumonia | 2 | 2019 | 5652 | 0.09 | Why? |
| Cohort Studies | 5 | 2019 | 36005 | 0.09 | Why? |
| Pregnancy | 4 | 2021 | 23879 | 0.09 | Why? |
| Pharmacoepidemiology | 1 | 2008 | 84 | 0.09 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 1454 | 0.09 | Why? |
| Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 1645 | 0.09 | Why? |
| Body Mass Index | 2 | 2018 | 4306 | 0.09 | Why? |
| Drug Utilization Review | 1 | 2008 | 72 | 0.09 | Why? |
| Australia | 2 | 2018 | 6306 | 0.09 | Why? |
| Risk | 2 | 2019 | 5288 | 0.09 | Why? |
| Angiotensin Receptor Antagonists | 2 | 2021 | 3892 | 0.09 | Why? |
| Diabetes Mellitus, Type 2 | 2 | 2019 | 6166 | 0.09 | Why? |
| Heart Rate | 1 | 2017 | 1527 | 0.09 | Why? |
| Parents | 2 | 2020 | 2758 | 0.08 | Why? |
| Arrhythmias, Cardiac | 2 | 2021 | 2510 | 0.08 | Why? |
| Drug Dosage Calculations | 2 | 2019 | 243 | 0.08 | Why? |
| Medical Records Systems, Computerized | 1 | 2008 | 159 | 0.08 | Why? |
| Symptom Assessment | 1 | 2021 | 4967 | 0.08 | Why? |
| Aged | 17 | 2021 | 215776 | 0.08 | Why? |
| Decision Making | 1 | 2021 | 3132 | 0.08 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 1261 | 0.08 | Why? |
| Bariatric Surgery | 1 | 2017 | 1298 | 0.08 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2021 | 5277 | 0.08 | Why? |
| Interrupted Time Series Analysis | 2 | 2021 | 868 | 0.08 | Why? |
| Treatment Outcome | 5 | 2019 | 51732 | 0.08 | Why? |
| Immunization Programs | 1 | 2019 | 2006 | 0.08 | Why? |
| Cognitive Dysfunction | 1 | 2018 | 1389 | 0.08 | Why? |
| Evidence-Based Medicine | 1 | 2019 | 3228 | 0.08 | Why? |
| Serologic Tests | 1 | 2020 | 4359 | 0.08 | Why? |
| Young Adult | 5 | 2021 | 93724 | 0.07 | Why? |
| Adult | 11 | 2021 | 244371 | 0.07 | Why? |
| Glucocorticoids | 1 | 2021 | 4431 | 0.07 | Why? |
| Saliva | 1 | 2021 | 4679 | 0.07 | Why? |
| Antineoplastic Agents | 1 | 2021 | 3550 | 0.07 | Why? |
| Asymptomatic Infections | 2 | 2021 | 7218 | 0.07 | Why? |
| Colorectal Neoplasms | 1 | 2019 | 1884 | 0.07 | Why? |
| Middle Aged | 16 | 2021 | 270681 | 0.07 | Why? |
| Hospitalization | 7 | 2021 | 54280 | 0.07 | Why? |
| Mental Disorders | 2 | 2018 | 6742 | 0.07 | Why? |
| Drug Therapy, Combination | 4 | 2019 | 7268 | 0.07 | Why? |
| Prevalence | 4 | 2020 | 25773 | 0.07 | Why? |
| Immunoassay | 1 | 2020 | 4485 | 0.07 | Why? |
| Dementia | 1 | 2018 | 1861 | 0.07 | Why? |
| Retrospective Studies | 7 | 2021 | 105322 | 0.07 | Why? |
| Heart Diseases | 1 | 2021 | 3503 | 0.06 | Why? |
| Gastrointestinal Diseases | 1 | 2018 | 2580 | 0.06 | Why? |
| Europe | 2 | 2018 | 12702 | 0.06 | Why? |
| Germany | 1 | 2018 | 9196 | 0.06 | Why? |
| Reproducibility of Results | 1 | 2019 | 11304 | 0.06 | Why? |
| Clinical Trials as Topic | 2 | 2019 | 7330 | 0.06 | Why? |
| Infant, Newborn | 3 | 2019 | 23105 | 0.06 | Why? |
| Patient Safety | 1 | 2017 | 4885 | 0.06 | Why? |
| Cross-Sectional Studies | 5 | 2021 | 53120 | 0.06 | Why? |
| Myocardial Infarction | 1 | 2017 | 3361 | 0.05 | Why? |
| Brain Ischemia | 1 | 2016 | 2813 | 0.05 | Why? |
| Referral and Consultation | 1 | 2017 | 4816 | 0.05 | Why? |
| Contact Tracing | 1 | 2021 | 8448 | 0.05 | Why? |
| Sex Factors | 1 | 2018 | 11014 | 0.05 | Why? |
| Health Personnel | 2 | 2021 | 29646 | 0.05 | Why? |
| Viral Load | 1 | 2021 | 15850 | 0.05 | Why? |
| Neoplasms | 2 | 2021 | 17251 | 0.05 | Why? |
| Age Factors | 5 | 2019 | 21039 | 0.05 | Why? |
| Penicillin V | 1 | 2019 | 10 | 0.05 | Why? |
| Aged, 80 and over | 5 | 2021 | 88759 | 0.05 | Why? |
| Hypertension | 1 | 2021 | 8895 | 0.05 | Why? |
| Primary Health Care | 1 | 2017 | 4839 | 0.05 | Why? |
| Age of Onset | 1 | 2020 | 557 | 0.05 | Why? |
| Survivors | 2 | 2021 | 2619 | 0.05 | Why? |
| Ohio | 1 | 2021 | 639 | 0.05 | Why? |
| Dosage Forms | 1 | 2017 | 11 | 0.04 | Why? |
| beta-Alanine | 1 | 2017 | 20 | 0.04 | Why? |
| Amphetamines | 1 | 2017 | 7 | 0.04 | Why? |
| Neuropsychiatry | 1 | 2018 | 81 | 0.04 | Why? |
| Risk Assessment | 5 | 2020 | 25439 | 0.04 | Why? |
| Immunoglobulin E | 1 | 2020 | 557 | 0.04 | Why? |
| United States | 3 | 2021 | 46150 | 0.04 | Why? |
| Drugs, Essential | 1 | 2018 | 117 | 0.04 | Why? |
| Mediterranean Region | 1 | 2017 | 276 | 0.04 | Why? |
| Diabetes Mellitus | 1 | 2019 | 8207 | 0.04 | Why? |
| Vaccines, Conjugate | 1 | 2019 | 328 | 0.04 | Why? |
| Republic of Korea | 2 | 2020 | 5858 | 0.04 | Why? |
| Secondary Care | 1 | 2017 | 160 | 0.04 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.04 | Why? |
| Aviation | 1 | 2017 | 77 | 0.04 | Why? |
| Attitude of Health Personnel | 1 | 2014 | 4741 | 0.04 | Why? |
| International Normalized Ratio | 1 | 2018 | 300 | 0.04 | Why? |
| Jordan | 1 | 2018 | 701 | 0.04 | Why? |
| England | 2 | 2017 | 5116 | 0.04 | Why? |
| Data Interpretation, Statistical | 1 | 2019 | 657 | 0.04 | Why? |
| False Positive Reactions | 1 | 2020 | 1338 | 0.04 | Why? |
| Steroids | 1 | 2021 | 904 | 0.04 | Why? |
| Remission Induction | 1 | 2018 | 950 | 0.03 | Why? |
| Benzimidazoles | 1 | 2017 | 275 | 0.03 | Why? |
| Bias | 1 | 2019 | 1109 | 0.03 | Why? |
| Natriuretic Peptide, Brain | 1 | 2021 | 1215 | 0.03 | Why? |
| Pharmacovigilance | 1 | 2018 | 501 | 0.03 | Why? |
| Chemoprevention | 1 | 2018 | 585 | 0.03 | Why? |
| Chi-Square Distribution | 1 | 2016 | 961 | 0.03 | Why? |
| Travel-Related Illness | 1 | 2021 | 1357 | 0.03 | Why? |
| Antibodies, Neutralizing | 1 | 2020 | 25288 | 0.03 | Why? |
| China | 4 | 2020 | 50654 | 0.03 | Why? |
| Pediatrics | 1 | 2008 | 2969 | 0.03 | Why? |
| Emergency Service, Hospital | 1 | 2017 | 14232 | 0.03 | Why? |
| Off-Label Use | 1 | 2017 | 553 | 0.03 | Why? |
| History, 20th Century | 1 | 2019 | 1282 | 0.03 | Why? |
| Osteoporosis | 1 | 2018 | 410 | 0.03 | Why? |
| Ventricular Dysfunction, Left | 1 | 2021 | 993 | 0.03 | Why? |
| Biomarkers | 3 | 2021 | 23361 | 0.03 | Why? |
| Health Services Research | 1 | 2018 | 756 | 0.03 | Why? |
| Body Weight | 1 | 2017 | 1074 | 0.03 | Why? |
| Follow-Up Studies | 2 | 2021 | 17020 | 0.03 | Why? |
| Glycated Hemoglobin A | 1 | 2019 | 1316 | 0.03 | Why? |
| Postpartum Period | 1 | 2017 | 936 | 0.03 | Why? |
| United States Food and Drug Administration | 1 | 2018 | 1276 | 0.03 | Why? |
| Mothers | 1 | 2021 | 1624 | 0.03 | Why? |
| Workload | 1 | 2021 | 1887 | 0.03 | Why? |
| Socioeconomic Factors | 2 | 2019 | 8495 | 0.03 | Why? |
| Family Characteristics | 1 | 2021 | 2551 | 0.03 | Why? |
| Antimicrobial Stewardship | 1 | 2018 | 931 | 0.03 | Why? |
| Peptide Fragments | 1 | 2021 | 2075 | 0.03 | Why? |
| Insulin | 1 | 2019 | 1316 | 0.03 | Why? |
| Taiwan | 1 | 2018 | 2556 | 0.03 | Why? |
| Phosphoproteins | 1 | 2020 | 4346 | 0.02 | Why? |
| Lymphocyte Count | 1 | 2021 | 4758 | 0.02 | Why? |
| Prospective Studies | 3 | 2021 | 43301 | 0.02 | Why? |
| Age Distribution | 1 | 2019 | 3567 | 0.02 | Why? |
| Drug Resistance, Bacterial | 1 | 2018 | 1414 | 0.02 | Why? |
| Odds Ratio | 1 | 2020 | 5861 | 0.02 | Why? |
| Hospitals, Teaching | 1 | 2017 | 1609 | 0.02 | Why? |
| Diet | 1 | 2021 | 2052 | 0.02 | Why? |
| Life Style | 1 | 2021 | 2708 | 0.02 | Why? |
| Community Health Services | 1 | 2017 | 1000 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2017 | 3776 | 0.02 | Why? |
| Nucleocapsid Proteins | 1 | 2020 | 3120 | 0.02 | Why? |
| Platelet Aggregation Inhibitors | 1 | 2018 | 1671 | 0.02 | Why? |
| Antibodies, Viral | 1 | 2020 | 51949 | 0.02 | Why? |
| Patient Compliance | 1 | 2017 | 1468 | 0.02 | Why? |
| Survival Analysis | 1 | 2021 | 7592 | 0.02 | Why? |
| Public Health Surveillance | 1 | 2020 | 3129 | 0.02 | Why? |
| Psychotic Disorders | 1 | 2017 | 924 | 0.02 | Why? |
| Electrocardiography | 1 | 2021 | 3957 | 0.02 | Why? |
| Hemorrhage | 1 | 2018 | 3013 | 0.02 | Why? |
| World Health Organization | 1 | 2018 | 4213 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2016 | 5440 | 0.02 | Why? |
| Polymerase Chain Reaction | 1 | 2020 | 6740 | 0.02 | Why? |
| Blood Coagulation | 1 | 2018 | 2768 | 0.02 | Why? |
| Time Factors | 2 | 2019 | 31397 | 0.02 | Why? |
| Japan | 1 | 2018 | 6653 | 0.02 | Why? |
| Blood Glucose | 1 | 2019 | 3642 | 0.02 | Why? |
| Computer Simulation | 1 | 2019 | 4982 | 0.02 | Why? |
| Cause of Death | 1 | 2018 | 4823 | 0.02 | Why? |
| Molecular Diagnostic Techniques | 1 | 2020 | 4239 | 0.02 | Why? |
| Electronic Health Records | 1 | 2016 | 3492 | 0.02 | Why? |
| Pandemics | 5 | 2021 | 389249 | 0.02 | Why? |
| Nasopharynx | 1 | 2021 | 10224 | 0.01 | Why? |
| Length of Stay | 1 | 2020 | 11042 | 0.01 | Why? |
| Logistic Models | 1 | 2017 | 9089 | 0.01 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.01 | Why? |
| Hospitals, University | 1 | 2014 | 4173 | 0.01 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.01 | Why? |
| Disease Progression | 1 | 2019 | 13580 | 0.01 | Why? |
| Data Collection | 1 | 2008 | 1769 | 0.01 | Why? |
| United Kingdom | 1 | 2019 | 18046 | 0.01 | Why? |
| Disease Transmission, Infectious | 1 | 2021 | 9044 | 0.01 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.01 | Why? |
| Global Health | 1 | 2018 | 13911 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2021 | 43792 | 0.01 | Why? |
| Practice Guidelines as Topic | 1 | 2017 | 15421 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2021 | 48226 | 0.01 | Why? |
| Prognosis | 1 | 2016 | 32490 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.01 | Why? |
| Internet | 1 | 2008 | 6204 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 37182 | 0.01 | Why? |
| Animals | 1 | 2018 | 78931 | 0.01 | Why? |
| Antiviral Agents | 1 | 2021 | 41703 | 0.01 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.00 | Why? |